Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E. Hostettler, Susanne Stowasser, Martin Kolb
European Respiratory Journal 2015 45: 1434-1445; DOI: 10.1183/09031936.00174914
Lutz Wollin
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stefan-lutz.wollin@boehringer-ingelheim.com
Eva Wex
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Pautsch
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisela Schnapp
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin E. Hostettler
2University Hospital Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Stowasser
3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
4McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 45 no. 5 1434-1445
DOI 
https://doi.org/10.1183/09031936.00174914
PubMed 
25745043

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Received September 23, 2014
  • Accepted January 5, 2015
  • Published online April 30, 2015.

Article Versions

  • previous version (March 5, 2015 - 06:49).
  • previous version (March 5, 2015 - 07:39).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright ©ERS 2015 ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Author Information

  1. Lutz Wollin1⇑,
  2. Eva Wex1,
  3. Alexander Pautsch1,
  4. Gisela Schnapp1,
  5. Katrin E. Hostettler2,
  6. Susanne Stowasser3 and
  7. Martin Kolb4
  1. 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  2. 2University Hospital Basel, Basel, Switzerland
  3. 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
  4. 4McMaster University, Hamilton, ON, Canada
  1. Stefan-Lutz Wollin, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Strasse 65, 88397 Biberach, Germany. E-mail: Stefan-lutz.wollin{at}boehringer-ingelheim.com
View Full Text

Funding

  • Boehringer Ingelheim

Article usage

Article usage: March 2015 to December 2020

AbstractFullPdf
Mar 2015640558572
Apr 2015455488341
May 20151843593523
Jun 2015450405248
Jul 2015293382185
Aug 2015264343161
Sep 201593428207
Oct 201527496259
Nov 201520427239
Dec 20159308145
Jan 201622306187
Feb 201629338106
Mar 201644385120
Apr 201615422131
May 201629327118
Jun 20161435299
Jul 201640290105
Aug 201635341153
Sep 201651493227
Oct 201634374148
Nov 201639478132
Dec 201625416120
Jan 201727334100
Feb 201728446120
Mar 201740558139
Apr 20172636499
May 20173140399
Jun 20172527491
Jul 20173326996
Aug 20173524972
Sep 20173132381
Oct 20172644989
Nov 20171739485
Dec 20171834459
Jan 20182737184
Feb 201843343109
Mar 201845408129
Apr 201840304103
May 201818373103
Jun 20181329968
Jul 20181631388
Aug 20182739887
Sep 20181532259
Oct 20182358597
Nov 20182558685
Dec 20183132176
Jan 2019634992
Feb 201924370108
Mar 20194541096
Apr 201928430138
May 201920488122
Jun 201934593157
Jul 201940626157
Aug 201939891132
Sep 2019731501200
Oct 2019401031227
Nov 201952898180
Dec 201932647154
Jan 202033663160
Feb 202036972128
Mar 202028923168
Apr 202023517120
May 202022602199
Jun 202018528150
Jul 202025556195
Aug 202025441128
Sep 202022718191
Oct 2020301109234
Nov 202024923191
Dec 202027867191

Altmetrics

PreviousNext
Back to top
View this article with LENS
Vol 45 Issue 5 Table of Contents
European Respiratory Journal: 45 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E. Hostettler, Susanne Stowasser, Martin Kolb
European Respiratory Journal May 2015, 45 (5) 1434-1445; DOI: 10.1183/09031936.00174914

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E. Hostettler, Susanne Stowasser, Martin Kolb
European Respiratory Journal May 2015, 45 (5) 1434-1445; DOI: 10.1183/09031936.00174914
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Idiopathic pulmonary fibrosis
    • PDGF/PDGFR signalling in pulmonary fibrosis
    • FGF/FGFR signalling in pulmonary fibrosis
    • VEGF/VEGFR signalling in pulmonary fibrosis
    • Nintedanib is a potent inhibitor of the receptor tyrosine kinases PDGFR, FGFR and VEGFR
    • Nintedanib interferes with essential fibrotic processes in a variety of in vitro assays and in vivo models
    • Clinical efficacy
    • Summary and conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Sleep-related breathing disorders and pulmonary hypertension
  • Targeting Cystic Fibrosis Inflammation in the Age of CFTR Modulators: Focus on Macrophages
  • Air-travel related TB incident follow up – effectiveness and outcomes: a systematic review
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society